Publications by authors named "Marc Van de Casteele"

Claim this Profile
F
Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases.
Daphne H Schoenmakers, Sibren van den Berg, Lonneke Timmers, Laura A Adang, Tobias Bäumer, Marc van de Casteele

Neurology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Maria Cavaller-Bellaubi, Wills Hughes-Wilson, Šárka Kubinová, Marc Van de Casteele, Evert Jan Van Lente

Orphanet J Rare Dis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.
Rick A Vreman, Daan van Hoof, Anna Nachtnebel, Joël Daems, Marc van de Casteele

Int J Technol Assess Health Care· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of national reimbursement reports to support formulary decisions of the hospital's Drug and Therapeutics Committee: a comparative analysis.
Barbara Claus, Sabrina Commeyne, Marc Van de Casteele, Sylvie Rottey

Int J Clin Pharm· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.
Hans-Georg Eichler, Roisin Adams, Einar Andreassen, Peter Arlett, Marc van de Casteele

Int J Technol Assess Health Care· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines.
Jane Moseley, Spiros Vamvakas, Michael Berntgen, Alison Cave, Xavier Kurz, Marc Van De Casteele

Br J Clin Pharmacol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations.
Giovanni Tafuri, Inês Lucas, Steve Estevão, Jane Moseley, Anne d'Andon, Marc Van de Casteele

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Patricia Vella Bonanno, Michael Ermisch, Brian Godman, Antony P Martin, Jesper Van Den Bergh, Marc van de Casteele

Front Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
Giovanni Tafuri, Margherita Pagnini, Jane Moseley, Marco Massari, Frank Petavy, Marc Van De Casteele

Br J Clin Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Michael Ermisch, Anna Bucsics, Patricia Vella Bonanno, Francis Arickx, Alexander Bybau, Marc van de Casteele

Front Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.
Sarah Kleijnen, Iris Pasternack, Marc Van de Casteele, Bernardette Rossi, Agnese Cangini

Int J Technol Assess Health Care· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piloting international production of rapid relative effectiveness assessments of pharmaceuticals.
Sarah Kleijnen, Iris Pasternack, Piia Rannanheimo, Jenni M Vuola, Marc Van de Casteele

Int J Technol Assess Health Care· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pdx1- and Ngn3-Cre-mediated PLAG1 expression in the pancreas leads to endocrine hormone imbalances that affect glucose metabolism.
Jeroen Declercq, Anujith Kumar, Conny Gysemans, Caterina Di Pietro, Anica Schraenen, Marc Van De Casteele

Cell Transplant· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis.
Wim Laleman, Anita Omasta, Marc Van de Casteele, Marcel Zeegers, Ingrid Vander Elst

Hepatology· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Halofuginone can worsen liver fibrosis in bile duct obstructed rats.
Marc Van de Casteele, Tania Roskams, Ingrid Van der Elst, Jos F van Pelt, Johan Fevery

Liver Int· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls.
Marc Van De Casteele, Jos F Van Pelt, Frederik Nevens, Johan Fevery, Jürg Reichen

Comp Hepatol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis